Hot Products
| Catalog No. | Information |
| CFN92695 | Sanggenol A Sanggenol A shows neuroprotective activity on glutamate-induced cell death in HT22 cells, with EC50 values of 34.03 ± 7.71 uM. Sanggenol A inhibits influenza A viral and pneumococcal neuraminidase (NA), it also disrupts the synergism between influenza A virus and pneumococcal NA in vitro, hence functioning as dual-acting anti-infectives. |
| CFN92787 | Sanggenol L Sanggenol L shows higher cytotoxicity against human oral tumor cell lines (HSC-2 and HSG) than against normal human gingival fibroblasts (HGF), it induces apoptosis via caspase activation and inhibition of NF-κB/IκBα phosphorylation as a potent chemotherapeutic agent for ovarian cancers. |
| CFN97893 | Sanggenol P Standard reference |
| CFN97979 | Sanggenon N Sanggenon N shows protective effects on t-BHP-induced oxidative stress with the EC50 value of 23.45 ± 4.72 uM. It inhibits lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophages. |
| CFN99593 | Sanggenone C Sanggenone C inhibits tumor cellular proteasomal activity and cell viability, via induction of cell cycle arrest and cell death , inhibiting the proteasome function. It inhibited NO production and iNOS expression by suppressing NF-κB activity and IκBα activation; inhibited TNF-alpha -stimulated PMN-HSC adhesion and expression of VCAM-1 by suppressing the activation of NF-kappaB. |
| CFN99704 | Sanggenone D Sanggenone D represents a new scaffold of positive GABAA receptor modulators, it also inhibits COX-2 activity (IC 50 = 73-100 μM). Sanggenone D has anti-inflammatory activity, it can inhibit NO production from lipopolysaccharide (LPS)-induced RAW 264.7 cells at > 10 uM; inhibition of nitric oxide production was mediated by suppression of iNOS enzyme induction but not by direct inhibition of iNOS enzyme activity. |
| CFN90836 | Sanggenone H Sanggenone H may have antiphlogistic activity, it attenuated the secretion of TNF-α and IL-1β and inhibited the NF-κB nuclear translocation in LPS-stimulated macrophages. |
| CFN92416 | Sanggenone K Reference standards. |
| CFN98259 | Sanguinarine Sanguinarine possesses anticancer, antimicrobial, anti-inflammatory, and antioxidant properties, it has therapeutic potential in preventing the neurodegenerative diseases, it may be used to develop a potential therapeutic drug for treating cardiac remodeling and heart failure and shows protective effects on teeth and alveolar bone health. Sanguinarine can inhibit osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways, and can protect against cardiac hypertrophy and fibrosis via inhibiting NF-κB activation. |
| CFN80234 | Sanguinarine chloride Sanguinarine chloride is a novel class of anti-Salmonella compounds, it could decrease the production of the SPI-1 type III secretion system main virulence proteins SipA and SipB and prevent the invasion of HeLa cells by Salmonella enterica serovar Typhimurium without affecting the growth of Salmonella. Sanguinarine chloride also shows cytotoxicity to cultured human cells from oral tissue. |
